id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-N-0009-0059,FDA,FDA-2021-N-0009,"Securing Updated and Necessary  Statutory Evaluations Timely;  Administrative Delay of Effective Date; 
Correction",Rule,Delay of Effective Date,2021-03-23T04:00:00Z,2021,3,2021-03-23T04:00:00Z,,2021-03-23T14:00:55Z,2021-05907,0,0,0900006484a75364
FDA-2021-N-0009-0001,FDA,FDA-2021-N-0009,"Making Permanent Regulatory Flexibilities Provided During the COVID–19 Public Health Emergency by Exempting Certain Medical Devices From Premarket Notification Requirements; Request for Information, Research, Analysis, and Public Comment on Opportunities for Further Science and Evidence-Based
Reform of Section 510(k) Program",Notice,Requests for Information (RFI),2021-01-15T05:00:00Z,2021,1,2021-01-15T05:00:00Z,2021-03-16T03:59:59Z,2024-11-06T23:43:54Z,2021-00787,1,0,09000064849f406a
FDA-2021-N-0009-0002,FDA,FDA-2021-N-0009,FDA Drug Review Timeline Transparency; Statement of Policy,Notice,Policy Statement,2021-01-15T05:00:00Z,2021,1,2021-01-15T05:00:00Z,,2021-01-21T17:10:01Z,2021-00786,0,0,09000064849f40de